Dose-finding Study in Platinum-Resistant Ovarian Cancer

Recurrent Platinum-resistant Ovarian Cancer Clinical Trial

Official title:
An Open-Label Phase I/II Study of GSK2110183 in Combination With Carboplatin and Paclitaxel in Subjects With Platinum-Resistant Ovarian Cancer

Status Completed

Clinical Trial Summary

- Dose-finding study of GSK2110183 administered in combination with carboplatin and paclitaxel to any subject with recurrent ovarian cancer.

- Safety and efficacy study of GSK2110183 administered in combination with carboplatin and paclitaxel to subjects with platinum-resistant ovarian cancer.

Clinical Trial Description

PKB116611 is an open-label Phase I/II study of the investigational drug GSK2110183 given in combination with carboplatin and paclitaxel to subjects with recurrent ovarian cancer. Phase I is a dose escalation evaluation of daily oral doses of GSK2110183 administered in combination with every 3 week carboplatin and paclitaxel to any subject with recurrent ovarian cancer. Phase II is a single arm evaluation of the clinical efficacy of the combination identified in Phase I to subjects with platinum-resistant ovarian cancer. ;

Study Design

Related Conditions & MeSH terms

Ovarian Neoplasms
Recurrent Platinum-resistant Ovarian Cancer

Clinical Trial Details

NCT number	NCT01653912
Study type	Interventional
Source	Accenture
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	November 2012
Completion date	November 2015

View Details

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT05145218` - A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer	Phase 3
	Recruiting	`NCT04068974` - Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer	Phase 2